3S Pharmaceuticals India Private Limited

3S Pharmaceuticals India Private Limited is a private limited company incorporated on October 26, 2021, in Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U51909MH2021PTC370327. It operates in the wholesale trade and commission trade sector, excluding motor vehicles and motorcycles. The authorized and paid-up capital of the company is ₹1.5 million. The registered office is located at A3, Bonanza Industrial Estate, A C Road, Ashok Nagar, Kandivali East, Mumbai, Maharashtra, 400101.

The company's leadership comprises Piyansh Omprakash Mantry, serving as the Managing Director, and Omprakash Shankarlal Mantry, who holds the position of Director. Both directors have been associated with the company since its inception. As of the latest available data, the company has not publicly disclosed its revenue or employee count.

3S Pharmaceuticals India Private Limited does not own or operate any manufacturing facilities. The company functions as a wholesaler and exporter, sourcing pharmaceutical products from various manufacturers to supply to its clients.

The key leadership of 3S Pharmaceuticals India Private Limited includes:

• Piyansh Omprakash Mantry: Managing Director, responsible for overseeing the company's strategic direction and operations.

• Omprakash Shankarlal Mantry: Director, involved in the company's management and decision-making processes.

Both directors have been associated with the company since its incorporation on October 26, 2021.

As of March 2026, 3S Pharmaceuticals India Private Limited has not publicly disclosed any regulatory filings, approvals, or market access statuses in the United States, European Union, United Kingdom, Australia, or Japan. The company primarily operates as a wholesaler and exporter, sourcing pharmaceutical products from various manufacturers to supply to its clients.

3S Pharmaceuticals India Private Limited has not publicly disclosed specific information regarding its penetration into emerging markets such as Africa, Latin America, or Southeast Asia. The company primarily operates as a wholesaler and exporter, sourcing pharmaceutical products from various manufacturers to supply to its clients.

3S Pharmaceuticals India Private Limited's geographic strategy focuses on sourcing pharmaceutical products from a diverse network of manufacturers across over 40 countries, including India, Turkey, the United States, Canada, Europe, the United Kingdom, Bangladesh, Japan, Hong Kong, New Zealand, and Brazil. This approach enables the company to offer a wide range of pharmaceutical products to its clients.

As of March 2026, 3S Pharmaceuticals India Private Limited has not publicly disclosed any FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection history. The company primarily operates as a wholesaler and exporter, sourcing pharmaceutical products from various manufacturers to supply to its clients.

3S Pharmaceuticals India Private Limited is a member of the Pharmaceuticals Export Promotion Council of India (PHARMEXCIL) and is registered with the Maharashtra Food and Drug Administration (FDA) under license numbers 20-B/MZ6-23015 and 21-B/MZ6-23016. Additionally, the company is an Authorized Economic Operator (AEO-T1) certified entity and has been audited and accredited by the World Health Organization – Good Storage and Distribution Practices (WHO-GSDP) by independent EU-based auditors.

3S Pharmaceuticals India Private Limited holds manufacturing licenses from the Maharashtra Food and Drug Administration (FDA) under license numbers 20-B/MZ6-23015 and 21-B/MZ6-23016. The company is also a member of the Pharmaceuticals Export Promotion Council of India (PHARMEXCIL) and is registered with the Maharashtra FDA.

As of March 2026, there are no publicly available records of Form 483 observations, warning letters, or import alerts issued to 3S Pharmaceuticals India Private Limited. The company primarily operates as a wholesaler and exporter, sourcing pharmaceutical products from various manufacturers to supply to its clients.

3S Pharmaceuticals India Private Limited operates in a competitive landscape with several key players in the pharmaceutical wholesale and export sector. Notable competitors include:

• 3S Corporation: A leading stockist, exporter, and wholesaler for anti-cancer drugs and oncology medicines, with a registered and government-recognized export house status.

• M S Asterisk Pharmaceuticals Pvt Ltd: Engaged in the wholesale trade of pharmaceutical products, including anti-cancer drugs and other specialty medicines.

• M S Medico Remedies Pvt Ltd: Specializes in the export and wholesale distribution of a wide range of pharmaceutical products, including oncology medicines.

While 3S Pharmaceuticals India Private Limited has a diverse product portfolio, its market share and position relative to these competitors are not publicly disclosed.

3S Pharmaceuticals India Private Limited differentiates itself through:

• Extensive Supplier Network: Sourcing products from over 40 countries, including India, Turkey, the United States, Canada, Europe, the United Kingdom, Bangladesh, Japan, Hong Kong, New Zealand, and Brazil.

• Regulatory Compliance: Holding manufacturing licenses from the Maharashtra FDA and being a member of PHARMEXCIL.

• Accreditations: Being an Authorized Economic Operator (AEO-T1) certified entity and audited and accredited by WHO-GSDP by independent EU-based auditors.

3S Pharmaceuticals India Private Limited's current strategic direction focuses on sourcing and exporting a wide range of pharmaceutical products, including oncology, critical care, diabetes, and heart care medicines. The company aims to serve wholesalers, suppliers, importers, doctors, hospitals, NGOs, and government institutions. Future outlooks or strategic plans are not publicly disclosed.

3S Pharmaceuticals India Private Limited has established a robust network of suppliers across over 40 countries, enabling it to source a diverse range of pharmaceutical products. The company emphasizes compliance with global standards of procurement, storage, and distribution of drugs. However, specific details regarding export volume, consistency, and reliability indicators are not publicly disclosed.

Importers should verify the following certifications when considering 3S Pharmaceuticals India Private Limited as a supplier:

• FDA Registration: Confirm the company's registration with the U.S. Food and Drug Administration (FDA) for exporting pharmaceutical products to the United States.

• WHO-GMP Certification: Verify the company's compliance with the World Health Organization's Good Manufacturing Practices (GMP) standards.

• EU GMP Certification: Ensure the company holds European Union Good Manufacturing Practices (GMP) certification for exporting to EU member countries.

• ISO Certification: Check for ISO certifications related to quality management systems and other relevant standards.

When conducting due diligence on 3S Pharmaceuticals India Private Limited, consider the following steps:

• Verify Regulatory Compliance: Confirm the company's compliance with relevant regulatory bodies, including the FDA, WHO, and EU authorities.

• Assess Financial Stability: Review the company's financial statements and credit history to evaluate its financial health.

• Evaluate Supplier Network: Assess the reliability and quality of the company's supplier network to ensure consistent product quality.

• Check Certifications: Verify the authenticity of certifications such as WHO-GMP, EU GMP, and ISO.

• Review Export History: Examine the company's export history and track record to gauge its experience and reliability